These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 4638222)

  • 1. Observations on patients with Parkinson's disease treated with L-dopa. I. Trial and evaluation of L-dopa therapy.
    van Wieringen A; Wright J
    S Afr Med J; 1972 Sep; 46(35):1262-6. PubMed ID: 4638222
    [No Abstract]   [Full Text] [Related]  

  • 2. Quantitative effects of L-dopa on different types of movements and muscle tone in Parkinsonian patients.
    Knutsson E; Mårtensson A
    Scand J Rehabil Med; 1971; 3(3):121-30. PubMed ID: 5156174
    [No Abstract]   [Full Text] [Related]  

  • 3. The modifying influence of L-dopa on the physical therapy program in Parkinson's disease.
    Blonsky ER; Minnigh EC
    Prog Phys Ther; 1970; 1(1):55-74. PubMed ID: 5523796
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical study of L-dopa in Parkinson's disease].
    Franken L; Noel G; Lhoas JP; Meyers C; Noel P; Ectors M
    Brux Med; 1972 Dec; 52(12):851-60. PubMed ID: 4575350
    [No Abstract]   [Full Text] [Related]  

  • 5. [Efficacy and side effects of L-dopa in patients with Parkinson's syndrome].
    Lombardo L
    Arch Invest Med (Mex); 1973; 4(3):215-24. PubMed ID: 4784173
    [No Abstract]   [Full Text] [Related]  

  • 6. Quantitative measurements of L-dopa therapy in Parkinson's disease.
    Webster DD
    Trans Am Neurol Assoc; 1969; 94():348-50. PubMed ID: 5374483
    [No Abstract]   [Full Text] [Related]  

  • 7. [Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)].
    Gehlen W; Eisenlohr JJ
    Nervenarzt; 1974 Jan; 45(2):22-9. PubMed ID: 4601993
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment of Parkinson's disease with L-dopa and with a combination of L-dopa and dopa-decarboxylase inhibitor].
    Agnoli A; Casacchia M; Reitano M; Ruggieri S; Barba C; Zamponi A
    Minerva Med; 1972 Dec; 63(89):4853-61. PubMed ID: 4566743
    [No Abstract]   [Full Text] [Related]  

  • 9. [Silent period in patients with Parkinson's disease treated with L-Dopa].
    Palao Sánchez A
    Arch Neurobiol (Madr); 1973; 36(1):47-56. PubMed ID: 4706780
    [No Abstract]   [Full Text] [Related]  

  • 10. Importance and pathogenesis of abnormal movements during L-dopa therapy of Parkinson's disease.
    Barbeau A
    Neurology; 1970 Apr; 20(4):377. PubMed ID: 5534982
    [No Abstract]   [Full Text] [Related]  

  • 11. Some quantitative behavioural changes in L-dopa therapy.
    Meier MJ; Baker AB; Martin WE
    Trans Am Neurol Assoc; 1970; 95():64-8. PubMed ID: 5514413
    [No Abstract]   [Full Text] [Related]  

  • 12. The influence of a previous thalamotomy on the L-dopa effects on mono-manual dexterity in parkinsonism.
    Knutsson E; Mårtensson A; Meyerson BA; Risberg AM
    Scand J Rehabil Med; 1973; 5(3):130-3. PubMed ID: 4754551
    [No Abstract]   [Full Text] [Related]  

  • 13. [New methods for measurement of the tremor and rigidity in patients with Parkinson's disease treated with L-Dopa].
    Paci A; Freddi A; Barba C
    Riv Neurol; 1973; 43(1):15-39. PubMed ID: 4698011
    [No Abstract]   [Full Text] [Related]  

  • 14. [Utility of L-dopa in the treatment of Parkinson's disease and parkinsonism-like diseases].
    Herskovits E; Matera R; Gacitua EF
    Medicina (B Aires); 1972; 32(1):10-4. PubMed ID: 5019629
    [No Abstract]   [Full Text] [Related]  

  • 15. [Disulfiram and L-dopa in patients with Parkinson's syndrome and in torsion dystonia].
    Serrano PA; Irigoyen M
    Prensa Med Mex; 1972; 37(7):246-50. PubMed ID: 4646433
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of a dihydromorphanthridine derivative in Parkinson's patients treated with L-dopa. A preliminary report.
    Wycis HT
    Confin Neurol; 1972; 34(2):130-5. PubMed ID: 4666056
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of Parkinson's syndrome with L-dopa].
    Ljung O
    Lakartidningen; 1972 Jun; 69(24):2940-4. PubMed ID: 5037135
    [No Abstract]   [Full Text] [Related]  

  • 18. L-dopa: effect on highest integrative functions in Parkinsonism.
    Guthrie TC; Dunbar HS; Weider A
    Trans Am Neurol Assoc; 1970; 95():250-2. PubMed ID: 5514382
    [No Abstract]   [Full Text] [Related]  

  • 19. Preliminary observations on L-dopa in the treatment of Parkinson's disease.
    Jelsma F; Roth R; Ross P; Davis J
    J Ky Med Assoc; 1971 Apr; 69(4):265-9. PubMed ID: 5577419
    [No Abstract]   [Full Text] [Related]  

  • 20. [Personal experience in the treatment of Parkinson's disease with L-Dopa].
    Figuerido JA; De la Herrán J
    Rev Clin Esp; 1970 Dec; 119(6):555-62. PubMed ID: 5509794
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.